Androgen receptor inhibitors: Novel therapeutic compounds and innovative screening method.

Tech ID: 19888 / UC Case 2008-123-0

FULL DESCRIPTION

Background:

Prostate cancer, alopecia, hepatocellular carcinoma, and acne vulgaris are a few examples of the myriad of diseases linked to androgen receptor signaling. These diseases have a significant impact on human health; for example, The American Cancer Society estimates that in 2009, prostate cancer will cause 27,360 deaths and 192,280 new cases will be diagnosed. In fact, one man in six will get prostate cancer in his lifetime and one in thirty-five will die from this disease. Androgen receptor inhibitors are the primary treatment option for androgen-related diseases. Current inhibitors prevent ligand binding to the androgen receptor, but these treatments can result in acquired resistance and serious side effects. Due to the limitations of current treatment options, alternative antiandrogen therapies are urgently needed.

Inventions:

Prominent UCSF scientists have discovered a suite of novel small molecule inhibitors of the androgen receptor. Using an innovative approach to avoid the pitfalls associated with current antiandrogen therapies, Dr Diamond’s team identified multiple compounds that inhibit the androgen receptor post-ligand binding. The team validated this work by demonstrating the ability of these compounds to inhibit endogenous androgen receptor activity in prostate cancer-derived cell lines. Further validation in animal models of prostate cancer is underway for many of the novel compounds. Significantly, the team demonstrated that one such compound, pyrvinium pamoate, inhibits androgen receptor signaling in vivo and induces prostate atrophy. Furthermore, pyrvinium synergizes with known inhibitors that prevent ligand binding (Jones et al. 2009).

In addition to the novel compounds, an assay to detect selective gene regulation by ligand dependent transcription factors has been developed. This assay could be used to uncover additional candidates for androgen receptor inhibition. The assay has been successfully tested on the glucocorticoid receptor and led to the discovery of selective modulators of this receptor for treatment of inflammation, allergic, and immune-mediated diseases.

Three patents have been filed on these technologies to provide a strong IP position for a licensee.

SUGGESTED USES

▶ Novel, potent inhibitors of androgen receptor signaling for the treatment of androgen-related diseases such as prostate cancer, alopecia, hepatocellular carcinoma, and acne vulgaris.
▶ Proven method to screen for additional inhibitors of androgen receptor signaling.

RELATED MATERIALS

Patents and Publications:

Invention: Novel androgen receptor agonists and methods of treating androgen-related diseases.

UC Case No: SF2008-123 and SF2006-079

Publications:  

Invention:  
Method to screen for modulators of ligand dependent transcription factors and selective modulators of the glucocorticoid receptor for treatment of inflammation, allergic and immune-related diseases.

UC Case No:  
SF2008-007

Patents:  
U.S. Provisional application pending

Publications:  

PATENT STATUS

<table>
<thead>
<tr>
<th>Country</th>
<th>Type</th>
<th>Number</th>
<th>Dated</th>
<th>Case</th>
</tr>
</thead>
<tbody>
<tr>
<td>United States Of America</td>
<td>Issued Patent</td>
<td>8,580,773</td>
<td>11/12/2013</td>
<td>2008-123</td>
</tr>
<tr>
<td>United States Of America</td>
<td>Issued Patent</td>
<td>8,354,538</td>
<td>01/15/2013</td>
<td>2008-123</td>
</tr>
</tbody>
</table>

ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

▶ A Method to Identify Novel Glucocorticoid Receptor Modulators

ADDRESS

UCSF Innovation Ventures
600 16th St, Genentech Hall, S-272, San Francisco, CA 94158

CONTACT

Tel: innovation@ucsf.edu
https://innovation.ucsf.edu

CONNECT

© 2009 - 2016, The Regents of the University of California
Terms of use Privacy Notice